Original Article

The Comparison of Immunohistochemistry Characteristics Between Breast Cancer Patients Under 35 Years Old and Above

Abstract

Increasing incidence rate of breast cancer in young women obligates investigations of clinical and pathological features in this age group. Less hormone receptor expressions and more aggressive behavior has been discussed in very young breast cancer patients. In this study pathological data of patients diagnosed with Invasive ductal carcinoma referred to Shariati hospital and Tehran cancer institute between 2015 and 2018 was evaluated in two groups : under 35 years old (Group1) and above (Group2). Each group contained 156 cases.  62.8% and 63.5% Estrogen and Progesterone Receptor expressionwas reported in Group 1 in comparison to 77.6% and 74.4% in Group 2 ( P value= 0.004 and 0.0038). Her2 expression was found in 41% and 21.2% in group 1 and 2 respectively ( P value= 0.0001). There was  41.2 ± 25.2 and 29.6 ± 21.7 reported of Ki67 in Group 1 and 2 ( P value= 0.001). In conclusion negative hormone receptor, positive Her2 expression and higher proliferation rates is found in breast cancer patients under 35-year-old

1. Guerra I, Algorta J, Díaz de Otazu R, Pelayo A, Fariña J. Immunohistochemical prognostic index for breast cancer in young women. Mol Pathol. 2003;56(6):323-7. https://doi.org/10.1136/mp.56.6.323
2. Fredholm H, Magnusson K, Lindström LS, Garmo H, Fält SE, Lindman H. Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat. 2016;160(1):131-143. https://doi.org/10.1007/s10549-016-3983-9
3. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al., Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324-30. https://doi.org/10.1200/JCO.2007.14.2471
4. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, et al., Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13: 273-279. https://doi.org/10.1093/annonc/mdf039
5. Sengal AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, Kantelhardt EJ, Mohamedani AA. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series. BMC Cancer. 2017;17(1):804. https://doi.org/10.1186/s12885-017-3805-4
6. Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol. 2016 Sep 20;34(27):3308-14. https://doi.org/10.1200/JCO.2015.65.8013
7. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in young women: clinicopathological features and biological specificity. Breast. 2003 Aug;12(4):247-50. https://doi.org/10.1016/S0960-9776(03)00095-X
Files
IssueVol 7 No 1 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ajs.v7i1.16348
Keywords
Breast Cancer Very Young Immunohistochemistry Prognosis
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Saeidpour G, Lashkari M, Saeidpour R, mir ali. The Comparison of Immunohistochemistry Characteristics Between Breast Cancer Patients Under 35 Years Old and Above. AJS. 2024;7(1):25-27.